+6.35(+0.41%)

+0.27(+0.44%)

-5.90(-0.44%)

-0.20(-1.17%)

-0.01(-0.71%)

Peregrine Pharmaceuticals to Present at Upcoming Conferences

TUSTIN, CA--(Marketwired - Aug 6, 2013) - Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM ), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that members of its management team will be presenting at the following conferences:

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.